• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.计算洞察 μ 阿片受体 G 蛋白偏向激活和失活机制。
Acta Pharmacol Sin. 2018 Jan;39(1):154-164. doi: 10.1038/aps.2017.158. Epub 2017 Nov 30.
2
Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation.运用分子动力学模拟研究 PZM21 在激活 μ-阿片受体时如何影响其构象状态。
Int J Mol Sci. 2020 Jul 1;21(13):4699. doi: 10.3390/ijms21134699.
3
Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.μ 阿片型 G 蛋白偶联受体募集β-arrestin 的机制。
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16346-16355. doi: 10.1073/pnas.1918264117. Epub 2020 Jun 29.
4
Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.结构-活性关系和发现一种 G 蛋白偏向性 μ 阿片受体配体,[(3-甲氧基噻吩-2-基)甲基]({2-[(9R)-9-(吡啶-2-基)-6-氧代螺[4.5]癸-9-基]乙基})胺(TRV130),用于治疗急性重度疼痛。
J Med Chem. 2013 Oct 24;56(20):8019-31. doi: 10.1021/jm4010829. Epub 2013 Oct 14.
5
The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.G 蛋白偏向性配体 PZM21 和 TRV130 是 μ 阿片受体介导的离子通道信号转导的部分激动剂。
Br J Pharmacol. 2019 Sep;176(17):3110-3125. doi: 10.1111/bph.14702. Epub 2019 Jul 9.
6
Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.μ 阿片受体 G 蛋白和β-arrestin 偏向配体联合应用的作用:预防抗伤害性耐受。
Mol Pain. 2017 Jan-Dec;13:1744806917740030. doi: 10.1177/1744806917740030.
7
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.临床上批准的 μ 阿片受体激动剂和 TRV130 的偏性激动作用不受结合和信号转导动力学的控制。
Neuropharmacology. 2020 Apr;166:107718. doi: 10.1016/j.neuropharm.2019.107718. Epub 2019 Jul 24.
8
The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies.G 蛋白信号偏向性化合物 TRV130:结构、作用部位和临床研究。
Curr Top Med Chem. 2020;20(31):2822-2829. doi: 10.2174/1568026620999201027224229.
9
How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways.奥利替定(TRV-130)如何结合并稳定一种μ-阿片受体构象状态,该状态选择性地触发G蛋白信号通路。
Biochemistry. 2016 Nov 22;55(46):6456-6466. doi: 10.1021/acs.biochem.6b00948. Epub 2016 Nov 7.
10
Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation.使用全原子分子动力学模拟探测偏态激动剂 PZM21 对μ-阿片受体的偏态激活。
Life Sci. 2021 Mar 15;269:119026. doi: 10.1016/j.lfs.2021.119026. Epub 2021 Jan 11.

引用本文的文献

1
Structural Determinants of Buprenorphine Partial Agonism at the μ-Opioid Receptor.丁丙诺啡对μ-阿片受体部分激动作用的结构决定因素
J Chem Inf Model. 2025 May 26;65(10):5071-5085. doi: 10.1021/acs.jcim.5c00078. Epub 2025 May 6.
2
A Bibliometric and Visual Analysis of Oliceridine Research (2013-2024).奥利替丁研究的文献计量学与可视化分析(2013 - 2024年)
Drug Des Devel Ther. 2025 Feb 24;19:1305-1321. doi: 10.2147/DDDT.S497186. eCollection 2025.
3
Three-Dimensional Structural Insights Have Revealed the Distinct Binding Interactions of Agonists, Partial Agonists, and Antagonists with the µ Opioid Receptor.三维结构见解揭示了激动剂、部分激动剂和拮抗剂与μ阿片受体的独特结合相互作用。
Int J Mol Sci. 2023 Apr 11;24(8):7042. doi: 10.3390/ijms24087042.
4
Tyrosine 7.43 is important for mu-opioid receptor downstream signaling pathways activated by fentanyl.酪氨酸7.43对于芬太尼激活的μ-阿片受体下游信号通路很重要。
Front Pharmacol. 2022 Sep 2;13:919325. doi: 10.3389/fphar.2022.919325. eCollection 2022.
5
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.新型 CB2 受体配体的设计、合成与生物活性:从正位变构调节剂和变构调节剂到双体/双位点配体。
J Med Chem. 2022 Jul 28;65(14):9918-9938. doi: 10.1021/acs.jmedchem.2c00582. Epub 2022 Jul 18.
6
Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor.激动剂与μ-阿片受体特异性结合的最新分子见解
Front Mol Biosci. 2022 Jun 13;9:900547. doi: 10.3389/fmolb.2022.900547. eCollection 2022.
7
Encoding mu-opioid receptor biased agonism with interaction fingerprints.利用相互作用指纹编码 μ 阿片受体偏向激动作用。
J Comput Aided Mol Des. 2021 Nov;35(11):1081-1093. doi: 10.1007/s10822-021-00422-5. Epub 2021 Oct 29.
8
Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.探讨混合作用 κ/μ 阿片受体双位点调节剂的变构调节的假定机制。
Future Med Chem. 2021 Mar;13(6):551-573. doi: 10.4155/fmc-2020-0308. Epub 2021 Feb 16.
9
Structural Insights into Ligand-Receptor Interactions Involved in Biased Agonism of G-Protein Coupled Receptors.结构洞察配体-受体相互作用涉及 G 蛋白偶联受体的偏激动作用。
Molecules. 2021 Feb 6;26(4):851. doi: 10.3390/molecules26040851.
10
Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.µ-阿片受体激动剂的药理学特征具有偏向 G 蛋白或β-arrestin 信号转导,以及受体激活过程中构象变化的计算研究。
Molecules. 2020 Dec 22;26(1):13. doi: 10.3390/molecules26010013.

本文引用的文献

1
Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.μ-阿片受体结合位点内的W320和Y328残基影响阿片类配体偏向性。
Neuropharmacology. 2017 May 15;118:46-58. doi: 10.1016/j.neuropharm.2017.03.007. Epub 2017 Mar 7.
2
Propagation of the Allosteric Modulation Induced by Sodium in the δ-Opioid Receptor.钠在δ-阿片受体中诱导的变构调节的传播
Chemistry. 2017 Apr 3;23(19):4615-4624. doi: 10.1002/chem.201605575. Epub 2017 Mar 20.
3
How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways.奥利替定(TRV-130)如何结合并稳定一种μ-阿片受体构象状态,该状态选择性地触发G蛋白信号通路。
Biochemistry. 2016 Nov 22;55(46):6456-6466. doi: 10.1021/acs.biochem.6b00948. Epub 2016 Nov 7.
4
Structure-based discovery of opioid analgesics with reduced side effects.基于结构的副作用减少的阿片类镇痛药的发现。
Nature. 2016 Sep 8;537(7619):185-190. doi: 10.1038/nature19112. Epub 2016 Aug 17.
5
GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling.G蛋白偶联受体-G蛋白-β-抑制蛋白超级复合物介导持续的G蛋白信号传导。
Cell. 2016 Aug 11;166(4):907-919. doi: 10.1016/j.cell.2016.07.004. Epub 2016 Aug 4.
6
New Technologies for Elucidating Opioid Receptor Function.用于阐明阿片受体功能的新技术。
Trends Pharmacol Sci. 2016 Apr;37(4):279-289. doi: 10.1016/j.tips.2016.01.001. Epub 2016 Jan 29.
7
Molecular switches of the κ opioid receptor triggered by 6'-GNTI and 5'-GNTI.由6'-GNTI和5'-GNTI触发的κ阿片受体的分子开关
Sci Rep. 2016 Jan 8;6:18913. doi: 10.1038/srep18913.
8
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.一项随机2期研究,调查μ-阿片受体的偏向性配体TRV130用于急性疼痛的静脉治疗。
Pain. 2016 Jan;157(1):264-272. doi: 10.1097/j.pain.0000000000000363.
9
GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation.GROMACS 4:高效、负载均衡和可扩展的分子模拟算法。
J Chem Theory Comput. 2008 Mar;4(3):435-47. doi: 10.1021/ct700301q.
10
Identification of a Conformational Equilibrium That Determines the Efficacy and Functional Selectivity of the μ-Opioid Receptor.确定一种决定μ-阿片受体功效和功能选择性的构象平衡。
Angew Chem Int Ed Engl. 2015 Dec 21;54(52):15771-6. doi: 10.1002/anie.201508794. Epub 2015 Nov 16.

计算洞察 μ 阿片受体 G 蛋白偏向激活和失活机制。

Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.

机构信息

Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.

Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

出版信息

Acta Pharmacol Sin. 2018 Jan;39(1):154-164. doi: 10.1038/aps.2017.158. Epub 2017 Nov 30.

DOI:10.1038/aps.2017.158
PMID:29188799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5758664/
Abstract

The μ opioid receptor (OR), a member of the class A subfamily of G-protein coupled receptors (GPCRs), is a major target for the treatment of pain. G-protein biased μ-OR agonists promise to be developed as analgesics. Thus, TRV130, the first representative μ-OR ligand with G-protein bias, has entered into phase III clinical trials. To identify the detailed G-protein-biased activation and inactivation mechanisms of the μ-OR, we constructed five μ-OR systems that were in complexes with the G-protein-biased agonists TRV130 and BU72, the antagonists β-FNA and naltrexone, as well as the free receptor. We performed a series of conventional molecular dynamics simulations and analyses of G-protein-biased activation and inactivation mechanisms of μ-OR. Our results, together with previously reported mutation results, revealed the operating mode of the activation switch composed of residues W and Y (Ballesteros/Weinstein numbering), the activity of which was responsible for down- and up-regulation, respectively, of the β-arrestin signaling, which in turn affected G-protein-biased activation of μ-OR. TRV130 was found to stabilize W by interacting with Y. In addition, we obtained useful information regarding μ-OR-biased activation, such as strong stabilization of W through a hydrophobic ring interaction in the TRV130 system. These findings may facilitate understanding of μ-OR biased activation and the design of new biased ligands for GPCRs.

摘要

μ 阿片受体(μOR)是 G 蛋白偶联受体(GPCR)A 亚家族的成员,是治疗疼痛的主要靶点。G 蛋白偏向性 μOR 激动剂有望被开发为镇痛药。因此,TRV130,即第一个具有 G 蛋白偏向性的 μOR 配体,已进入 III 期临床试验。为了确定 μOR 的详细 G 蛋白偏向性激活和失活机制,我们构建了五个与 G 蛋白偏向性激动剂 TRV130 和 BU72、拮抗剂 β-FNA 和纳曲酮以及游离受体结合的 μOR 系统。我们进行了一系列常规分子动力学模拟和 μOR 的 G 蛋白偏向性激活和失活机制分析。我们的结果与先前报道的突变结果一起,揭示了由残基 W 和 Y 组成的激活开关的工作模式(Ballesteros/Weinstein 编号),其活性分别负责下调和上调β-抑制素信号,从而影响 μOR 的 G 蛋白偏向性激活。TRV130 被发现通过与 Y 相互作用稳定 W。此外,我们获得了有关 μOR 偏向性激活的有用信息,例如在 TRV130 系统中通过疏水性环相互作用对 W 进行强稳定。这些发现可能有助于理解 μOR 的偏向性激活和 GPCR 新的偏向性配体的设计。